Publicacións en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (37)

2024

  1. Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register

    Seminars in Arthritis and Rheumatism, Vol. 64

  2. Red flags for clinical suspicion of eosinophilic granulomatosis with polyangiitis (EGPA)

    European Journal of Internal Medicine, Vol. 128, pp. 45-52

  3. Salivary gland ultrasound features in sicca syndrome secondary to immunotherapy with checkpoint inhibitors

    Clinical Rheumatology

2023

  1. Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: A monocentric survey'

    Annals of the Rheumatic Diseases

  2. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study

    RMD open, Vol. 9, Núm. 1

  3. Impact of ultrasound limitation to assess aortitis in patients with giant cell arteritis: comparative study with FDG-PET/CT

    RMD open, Vol. 9, Núm. 3

  4. Oral or pulse glucocorticoid use at the onset of giant cell arteritis and its influence on the risk of relapse: a retrospective study

    Rheumatology International, Vol. 43, Núm. 7, pp. 1333-1340

  5. Performance of the 2022 ACR/EULAR giant cell arteritis classification criteria for diagnosis in patients with suspected giant cell arteritis in routine clinical care

    RMD open, Vol. 9, Núm. 2

  6. Salivary gland ultrasound in clinical practice: What is its real usefulness?

    Reumatologia Clinica, Vol. 19, Núm. 5, pp. 260-265

  7. The role of ultrasound and FDG-PET/CT to detect extracranial artery involvement in patients with suspected large vessel vasculitis

    Modern rheumatology, Vol. 33, Núm. 3, pp. 549-556

2022

  1. Diagnostic value of ultrasound halo count and Halo Score in giant cell arteritis: A retrospective study from routine care

    Annals of the Rheumatic Diseases

  2. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies

    RMD open, Vol. 8, Núm. 1

  3. Impact of cardiovascular risk on the diagnostic accuracy of the ultrasound Halo Score for giant cell arteritis

    Arthritis Research and Therapy, Vol. 24, Núm. 1

  4. Local adaptation of recommendation-based materials for shared decision-making and management of comorbidity in rheumatoid arthritis

    Clinical and experimental rheumatology, Vol. 40, Núm. 5, pp. 975-979

  5. Long-Term Retention Rate of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis in a Real-Life Setting

    Journal of Clinical Rheumatology, Vol. 28, Núm. 1, pp. E150-E155

  6. New-onset giant cell arteritis following COVID-19 mRNA (BioNTech/Pfizer) vaccine: a double-edged sword?

    Clinical Rheumatology

  7. Position of the Spanish Society of Rheumatology (SER) and the Spanish Society for Bone Research and Mineral Metabolism (SEIOMM) on romosozumab

    Reumatologia Clinica, Vol. 18, Núm. 7, pp. 383-386

  8. The reality of Rheumatology in Spain and its autonomous communities before the pandemic

    Reumatologia Clinica, Vol. 18, Núm. 8, pp. 486-489

  9. Ultrasound Doppler enthesitis shows sensitivity to change after biological therapy in spondyloarthritis and psoriatic arthritis patients

    Scandinavian Journal of Rheumatology, Vol. 51, Núm. 3, pp. 196-204

  10. Ultrasound intima media thickness cut-off values for cranial and extracranial arteries in patients with suspected giant cell arteritis

    Frontiers in Medicine, Vol. 9